Esperion(US:ESPR)2026-01-12 13:00Financial Projections - Preliminary full-year 2025 U.S. net product sales are projected to be between $156 million and $160 million, representing a 35% to 38% increase compared to full-year 2024[1]. - Total preliminary revenue for 2025 is expected to be between $400 million and $408 million, a 20% to 23% increase compared to full-year 2024, and approximately 55% to 59% increase excluding one-time milestones[1]. - Cash and cash equivalents are approximately $168 million at year-end 2025[1]. - Operating expenses for full-year 2026 are expected to be between $210 million and $245 million[1]. Growth Strategy - The Vision 2040 growth strategy aims to expand the cardiometabolic franchise and pipeline into rare hepatic and renal diseases[1]. - Esperion plans to introduce two triple combination products that could lower LDL-C by over 60%, potentially rivaling existing therapies[9]. - Esperion's strategic partner Daiichi Sankyo Europe achieved double-digit quarterly growth and expanded availability of bempedoic acid therapies across 30 EU countries[12]. - The company completed a $75 million capital raise in 2025 to enhance financial flexibility for commercial expansion and pipeline development[13]. - Esperion initiated studies for ESP-2001, a potential blockbuster treatment for primary sclerosing cholangitis, with a market opportunity exceeding $1 billion annually[16]. Forward-Looking Statements - The press release includes forward-looking statements regarding Esperion's marketing strategy, commercialization, and business development plans[30]. - Esperion anticipates future profitability and outlines expected operational expenses and cash runway[30]. - The company is focused on clinical development, including the timing and plans for the CLEAR Outcomes study[30]. - Risks and uncertainties could significantly impact Esperion's net sales and growth of commercial products[30]. - The company disclaims any obligation to update forward-looking statements unless required by law[30].